FindMyKOL
Clinical trialNCT02269267CompletedPhase 2Interventional

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

SponsorMedical College of WisconsinEnrollment173Leukemia, Myeloid, Chronic
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Helen Diller Family Comprehensive Cancer Center University of California

    San Francisco, California, United States

  • Moffit Cancer Center

    Tampa, Florida, United States

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia, United States

  • the University of Chicago

    Chicago, Illinois, United States

  • the University of Chicago Medicine Comprehensive Cancer Center at Silver Cross

    New Lenox, Illinois, United States

  • Beth Israel Deaconess Medical Center (satellite Site of Dana Farber)

    Boston, Massachusetts, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

  • Karmanos Cancer Institute of Wayne State University

    Detroit, Michigan, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Weill Medical College of Cornell University

    New York, New York, United States

  • Duke University Medical Center

    Durham, North Carolina, United States

  • Md Anderson Cancer Center

    Houston, Texas, United States

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah, United States

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, United States

  • Froedtert Hospital & Medical College of Wisconsin

    Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BosutinibDasatinibImatinibNilotinib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Dec 2014
Primary completion
6 Apr 2021
Completion
6 Apr 2022
Last update posted
3 Mar 2023
Registered enrollment
173
Registry id
NCT02269267
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.